Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Leuprolide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 2/20 | 0.86 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.84 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.80 |
| ▸ | APLNR | P35414 | 4/20 | 0.65 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leuprolide SCHEMBL7751433 | 1.00 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Deslorelin SCHEMBL1649660 | 1.00 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL21540132 | 1.00 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL4585 | 1.00 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL3915060 | 0.99 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL6448301 | 0.99 | GNRHR (0.86) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| SCHEMBL21109135 | 0.99 | GNRHR (0.84) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL570851 | 0.99 | ABCC2 (0.87) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL847084 | 0.99 | ABCC2 (0.87) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Leuprolide SCHEMBL3174 | 0.99 | ABCC2 (0.87) | GNRHRABCC2PTGS1APLNRCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210205245-A1 | LIPOSOMAL ANTICANCER COMPOSITIONS | IRISYS, INC. | 2021-07-08 | — | — | US | disclosed |
| US-11033520-B2 | Liposomal anticancer compositions | IRISYS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20190269635-A1 | LIPSOMAL ANTICANCER COMPOSITIONS | IRISYS, INC. | 2019-09-05 | — | — | US | disclosed |
| US-20120029167-A1 | AUTO MAGNETIC METAL SALEN COMPLEX COMPOUND | YOSHIHIRO ISHIKAWA (JP) | 2012-02-02 | — | — | US | disclosed |
| US-7531162-B2 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531162-B2 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2009-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190269635-A1 | LIPSOMAL ANTICANCER COMPOSITIONS | LIPA, DLST, LIPC | GNRHR 4281/4885ABCC2 713/4885PTGS1 3652/4885 |
| US-11033520-B2 | Liposomal anticancer compositions | OTC, LIPA, TP53 | GNRHR 3752/4885ABCC2 481/4885PTGS1 3029/4885 |
| US-20120029167-A1 | AUTO MAGNETIC METAL SALEN COMPLEX COMPOUND | SDHB, SDHA, SLC40A1 | GNRHR 1788/4885ABCC2 527/4885PTGS1 2657/4885 |
| US-20210205245-A1 | LIPOSOMAL ANTICANCER COMPOSITIONS | LIPA, PHOSPHO1, MCL1 | GNRHR 3088/4885ABCC2 499/4885PTGS1 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.